Weekly Recap: BIMZELX-driven H1 growth and galvokimig midstage readout
UCB S.A. (EURONEXT:UCB) ramped H1 growth and raised guidance on BIMZELX momentum and expanding access, while pipeline progress across atopic dermatitis, epilepsy and T—cell engagers and a midstage galvokimig readout next year—plus deals like Candid and Neurona—position the firm to target early-stag…